Vaccizone

Vaccizone Selects Exothera for Process Development and GMP Manufacturing of its SARS CoV 2 Vaccine Based on Proprietary ASC Technology

Istanbul, Turkey, 6 July 2022: Life Science Newswire - Vaccizone, a vaccine development company focusing on innovative antigen delivery technology, selected Exothera S.A. to fast-track process development of its SARS CoV 2 vaccine for European clinical trials.
Rumeli Hisarı Mah. Bebek Yolu Sok. Boğaziçi Üniversitesi Kuzey Kampüs Teknopark No:2/5, 202, Sarıyer-İstanbul